These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29127864)

  • 1. Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension.
    Roldan T; Villamañán E; Rios JJ; Waxman AB
    Thromb Res; 2017 Dec; 160():83-90. PubMed ID: 29127864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers.
    Roldan T; Rios JJ; Villamañan E; Waxman AB
    Pulm Circ; 2017; 7(3):692-701. PubMed ID: 28677986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A descriptive evaluation of warfarin use in patients with pulmonary arterial hypertension.
    Irwin AN; Johnson SG; Joline BR; Delate T; Witt DM
    Thromb Res; 2014 May; 133(5):790-4. PubMed ID: 24642007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study.
    Costa GL; Lamego RM; Colosimo EA; Valacio RA; Moreira Mda C
    Clin Ther; 2012 Jul; 34(7):1511-20. PubMed ID: 22717417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients.
    Rivera-Caravaca JM; Viedma-Viedma I; Roldán V
    Biol Res Nurs; 2017 Mar; 19(2):198-205. PubMed ID: 27680769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).
    Ansell J; Hollowell J; Pengo V; Martinez-Brotons F; Caro J; Drouet L
    J Thromb Thrombolysis; 2007 Apr; 23(2):83-91. PubMed ID: 17221328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
    Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW
    Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events.
    Pivatto Junior F; Scheffel RS; Ries L; Wolkind RR; Marobin R; Barkan SS; Amon LC; Biolo A
    Arq Bras Cardiol; 2017 Apr; 108(4):290-296. PubMed ID: 28538758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review.
    Johnson SR; Mehta S; Granton JT
    Eur Respir J; 2006 Nov; 28(5):999-1004. PubMed ID: 17074918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials.
    Proietti M; Lane DA; Lip GY
    Int J Cardiol; 2016 Aug; 216():168-72. PubMed ID: 27156060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the quality control of anticoagulation in patients with atrial fibrillation in a Primary Health Care Area of Madrid].
    Habashneh Sánchez S; Abad Díaz I; Tinajero Valle CP; Cortés Palmero A; Lobón Agúndez MC; Muñoz Fernández C
    Semergen; 2016; 42(5):287-92. PubMed ID: 26272881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink.
    Macedo AF; Bell J; McCarron C; Conroy R; Richardson J; Scowcroft A; Sunderland T; Rotheram N
    Thromb Res; 2015 Aug; 136(2):250-60. PubMed ID: 26073321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?
    Khan MS; Usman MS; Siddiqi TJ; Khan SU; Murad MH; Mookadam F; Figueredo VM; Krasuski RA; Benza RL; Rich JD
    Circ Cardiovasc Qual Outcomes; 2018 Sep; 11(9):e004757. PubMed ID: 30354550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?
    Margelidon-Cozzolino V; Delavenne X; Catella-Chatron J; De Magalhaes E; Bezzeghoud S; Humbert M; Montani D; Bertoletti L
    Blood Rev; 2019 Sep; 37():100579. PubMed ID: 31113643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.